FLC
AVDL

Fifth Lane Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Fifth Lane Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,182
Closed -$521K – 67
2025
Q4 		$521K Buy
+24,182
New +$469K 0.4% 43

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Fifth Lane Capital's AVDL Position: Q1 2026 in Review

Fifth Lane Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 24,182 shares — an estimated $521K sold.

Fifth Lane Capital first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $521K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Fifth Lane Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fifth Lane Capital sold 24,182 Avadel Pharmaceuticals shares in Q1 2026, an estimated $521K.
  • Fifth Lane Capital first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Fifth Lane Capital's Avadel Pharmaceuticals position peaked at $521K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Fifth Lane Capital's 13F filing for Q1 2026, filed 15 May 2026.